HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Kezar Life Sciences (NASDAQ:KZR) and maintained a price target of $7.
August 14, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Kezar Life Sciences and maintained a price target of $7.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100